logo
Assisted dying bill: How both sides of debate reacted to historic vote

Assisted dying bill: How both sides of debate reacted to historic vote

Sky News3 hours ago

People on both sides of the assisted dying debate have told Sky News how they feel about the outcome of today's vote – and while some are popping open champagne, others are "incredibly disappointed".
More than 300 MPs this afternoon backed a bill that gives people in England and Wales who have less than six months to live the right to apply for an assisted death.
Each request will be evaluated by two doctors and a panel featuring a social worker, senior legal figure and psychiatrist.
Today's historic vote means the Terminally Ill Adults (End of Life) Bill will now go to the House of Lords for further scrutiny before becoming law.
Following the landmark vote, individuals for and against it have shared their feelings on the result.
Frank Tate-Sutton - For
6:04
Frank Tate-Sutton is terminally ill and told Sky News she's relieved the bill has passed, even though the law won't be changed in time for her.
"These are happy tears," she said. "I am emotional. It's a very difficult subject for everybody."
Ms Tate-Sutton said her quality of life is "very important - and I'm losing it".
"I don't want to die without dignity, without it being my choice, without my family knowing that this is what I want," she continued.
"As much as they [my family] want me alive, do they want to see me lying in my living room in a hospital bed, taking all these drugs, not being able to talk, not being able to control my bodily functions?
"That is not a life, for me - living on all the medications and not being able to exist without that… the side effects and everything."
Mike Smith - Against
5:20
Mike Smith is a spokesperson for the disability rights group Not Dead Yet - and he has been left "incredibly disappointed" by the outcome of the vote.
"This particular bill had so many failings in the way safeguards are constructed and the significant scope for coercion, whether it's overt or subliminal," he said.
Mr Smith says he fears some people will "end up ending their lives earlier than they should do or want to".
"There are so many disabled people around the country that have told us they're absolutely scared."
"I think it's this inherent fear people have about being disabled that drives this very emotional response on this really complex topic," he explained.
"What we know is, with good palliative care, social care, access to housing and an income, many disabled people ... can lead amazing lives."
6:48
Rebecca Wilcox and her TV presenter mother Dame Esther Rantzen, who has terminal cancer, have long been campaigning for a change to the UK's law on assisted dying.
Speaking from Parliament Square as fellow supporters of the bill popped champagne behind her, Ms Wilcox described today's vote as "an extraordinary moment".
"It means so much to me," she said. "I spoke to mum and her one word to describe it was 'wow'.
"She didn't think she was going to live to see the debate, let alone a conclusion that went our way."
In response to concerns about safeguarding, she said it will "bring in layer upon layer of safeguards".
"We're going to have scrutiny upon scrutiny for every case and at the moment, there is no scrutiny," she said. "Coercion could be happening as we speak.
"There is now protection for vulnerable people, by having this bill passed."
Dr Gordon Macdonald - Against
Dr Macdonald said the bill passing with a majority of 23 - less than half what its second reading achieved - is proof that "the more people have thought about this issue, the more they've had doubts".
The doctor, who is the CEO of anti-euthanasia organisation Care not Killing, said: "We will see what happens when it gets to the [House of] Lords, the Lords will hopefully give it more rigorous scrutiny than happened in the Commons".
His biggest concern is "for people who are vulnerable, who will feel pressure to end their lives".
"That might come from external forces, but it's more likely to just be internalised pressure," Dr Macdonald said.
"They'll feel they're a burden on their family and friends, conscious of the cost of care, and think they should do the decent thing, as they would see it in that thinking."
It's "of course a terrible message for society to send out to people," he said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Reckless cyclists who kill pedestrians could be jailed for life as government set to crackdown on 'nightmare' E-bikes
Reckless cyclists who kill pedestrians could be jailed for life as government set to crackdown on 'nightmare' E-bikes

Daily Mail​

time44 minutes ago

  • Daily Mail​

Reckless cyclists who kill pedestrians could be jailed for life as government set to crackdown on 'nightmare' E-bikes

Reckless cyclists who kill or seriously injure pedestrians will face tougher sentences in line with motoring offences. Under changes to the Crime and Policing Bill, a cyclist who kills someone by riding dangerously could face life in prison. Causing serious injury by dangerous cycling – or causing death by careless or inconsiderate cycling – could be met with five years in prison, a fine or both. A serious injury caused by careless or inconsiderate cycling could result in a two-year prison sentence, a fine or both. The law change, which cleared the Commons this week, includes legal e-bikes as well as pedal cycles, the Government said. The Tories agreed to change the law after campaigning by Conservative grandee Iain Duncan Smith – only for it to fall foul of the early general election last year. Sir Iain has worked with Matthew Briggs, whose wife Kim died from head injuries after a collision with a cyclist in London in 2016. Charlie Alliston, who was riding a fixed-gear bike with no front brake, was found guilty of causing bodily harm by 'wanton or furious driving' – a crime under the 1861 Offences Against the Person Act – but cleared of manslaughter. Sir Iain said the change in the law would mean that for the first time there would be specific punishments for 'reckless, dangerous cycling causing injury or death'. The Bill includes e-bikes, which he said were becoming a 'major nightmare' for police, with crimes being committed using them as well as being ridden dangerously. Sir Iain said he hoped the legislation would make it 'worthwhile' for police to arrest someone for such offences. 'Now you have very specific criminal offences at those who misuse and damage people's lives and kill them,' he told BBC Radio 4's Today programme. 'That will now be a specific crime, and will include e-bikes – riding on pavements, smashing into people, causing problems – that becomes a criminal offence.' The Government said it was changing the law to ensure there is an 'appropriate framework of offences to punish dangerous and careless behaviour that results in serious harm to other road users'. The Ministry of Justice said the new offences 'introduce penalties equivalent to those in place if the same level of harm is caused by drivers of other vehicles'. In 2023, four pedestrians were killed and 185 seriously injured after being hit by a cyclist, according to government figures. On average, three pedestrians have been killed per year by cyclists over the past decade.

Ozempic-maker's new fat-busting drug cuts body weight by a quarter - and it comes as a jab or a PILL
Ozempic-maker's new fat-busting drug cuts body weight by a quarter - and it comes as a jab or a PILL

Daily Mail​

timean hour ago

  • Daily Mail​

Ozempic-maker's new fat-busting drug cuts body weight by a quarter - and it comes as a jab or a PILL

A new fat-busting drug that is available as a jab or tablet helps patients lose up to a quarter of their body weight, studies suggest. People who received higher doses of amycretin as a weekly injection lost 24.3 per cent of their body weight after 36 weeks of treatment. And those taking daily tablets lost an average of 13.1 per cent of their body weight after 12 weeks, the early stage trials found. Weight loss jabs have been hailed as transformative by NHS leaders. But tablets could be the next big breakthrough in the nation's fight against obesity as they are likely to appeal to a wider audience who are uncomfortable with injecting themselves. An estimated 1.5million Britons use weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out fat jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body—GLP-1 and the amylin receptor. In comparison to amycretin, trials pivotal to getting semaglutide—the ingredient behind Ozempic—approved, show it helped users shed up to 15 per cent of their body weight over 68 weeks. And studies have found rival jab Mounjaro can help obese people lose up to 22.5 per cent of their body weight in 72 weeks. The new amycretin trial involved 125 adults, who took weekly injections of the drug. Those taking the highest dosage (60mg) lost 24.3 per cent after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment, according to findings published in medical journal The Lancet. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1 per cent of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7 per cent, with a third of participants losing 25 per cent or more of their body weight after 72 weeks. GLP-1 injections suffered global shortages after celebrity users sparked a surge in popularity and the NHS has warned people against buying them from unauthorised sources. Professor Sir Stephen Powis, national medical director at NHS England, last week told the NHS ConfedExpo conference in Manchester that weight loss jabs could be doled out as widely as statins if competition in the market brings their price down The country's top doctor warned obesity costs the NHS £11.4billion every year and described the financial burden as 'unsustainable'. From Monday, GPs will be able to prescribe the fat jab mounjaro - also known as tirzepatide - for the first time, in what he labelled an 'exciting milestone'.

Weight loss pill set to rival injections after promising studies
Weight loss pill set to rival injections after promising studies

The Independent

timean hour ago

  • The Independent

Weight loss pill set to rival injections after promising studies

A new daily weight loss pill has shown promising results in initial studies. Researchers say amycretin, which can be offered by injection or tablet, helped patients lose a significant amount of weight in the first trials. Those who received higher doses of amycretin as a weekly jab lost 24.3 per cent of their body weight after 36 weeks of treatment, while patients who took daily tablets lost an average of 13.1 per cent of their body weight after 12 weeks. While weight loss jabs have been hailed as transformative by NHS leaders, injections come with additional work for over-stretched health services, so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3 per cent after 36 weeks of treatment. It also showed signs of improving blood sugar levels. Side effects included nausea and vomiting, and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1 per cent of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association 's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7 per cent, with a third of participants losing 25 per cent or more of their body weight after 72 weeks.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store